Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00939692 · ClinicalTrials.gov registry record · Phase 1

Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fasted Conditions

A Phase 1 study, sponsored by Torrent Pharmaceuticals Limited.

Completed
Registry status
Phase 1
Development phase
26
Enrollment target

NCT00939692: Completed Phase 1 study, sponsored by Torrent Pharmaceuticals Limited.

NCT00939692 is a Phase 1 study that has completed, run by Torrent Pharmaceuticals Limited. The registered enrollment target is 26 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00939692, a Phase 1 study, has completed, sponsored by Torrent Pharmaceuticals Limited.

COMPLETED
Registry status
Phase 1
Development phase
26 participants
Enrollment target

Study Summary

* Objective: * Compare the bioequivalence of a test topiramate formulation (Torrent Pharmaceuticals Limited) to an equivalent oral dose of the commercially available topiramate (Topamax®, Ortho-McNeil Neurologics, Inc.) in a test population of 26 adult subjects under fasted conditions. * Clinical Design: * Studies were Randomized, Two-Way Crossover, Single-Dose,Open-Label in healthy human adult subjects.

Primary Outcome

The maximum or peak concentration that the drug reaches in the plasma

Interventions

  • DRUG Topiramate

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2007-01
Est. Completion 2007-04
Phase Phase 1
Torrent Pharmaceuticals Limited

7 total trials

What the finished NCT00939692 record still lists

NCT00939692 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower).

The record links to 0 conditions, and to 1 intervention - of which Topiramate is the first listed.

NCT00939692 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00939692 about?

NCT00939692 is a clinical study titled "Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fasted Conditions". * Objective: * Compare the bioequivalence of a test topiramate formulation (Torrent Pharmaceuticals Limited) to an equivalent oral dose of the commercially available topiramate (Topamax®, Ortho-McNeil Neurologics, Inc.) in a test population of 26 adult subjects under fasted conditions. * Clinical...

What is the current status of trial NCT00939692?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2007-01. Estimated completion is 2007-04.

What interventions are being tested in trial NCT00939692?

The interventions under investigation include: Topiramate (DRUG).

Who is sponsoring clinical trial NCT00939692?

This trial is sponsored by Torrent Pharmaceuticals Limited, which has 7 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00939692's enrollment target sits among peer trials

26 1482nd of 2000 higher than 506 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02646475 · 26 participants · Phase 1

    Metabolic Effects of Angiotensin-(1-7)

  • NCT03603223 · 26 participants · Phase 2

    Pembrolizumab in Treating Participants With Leukoplakia

  • NCT04063592 · 26 participants · NA

    AMI Construction in Lower Extremity Residual Limbs

  • NCT04906460 · 26 participants · Phase 1

    Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00939692, the US trial registry maintained by the National Library of Medicine. NCT00939692 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.